Durect, a specialty pharmaceutical company, outperformed the S&P 500 this year.
1 report, 1 independent
Updated Aug 13
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Durect, a specialty pharmaceutical company, outperformed the S&P 500 this year.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Durect (United States)
company in Cupertino, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- ZacksDurect (DRRX) Reports Q2 Loss, Tops Revenue Estimates Durect (DRRX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss o